Radiopharmaceuticals startup RayzeBio submits IPO pitch, foreshadowing expected post-Labor Day bump in biotech listings

Kyle LaHucik

Senior Reporter

A Phase III-stage radiopharmaceuticals biotech has filed to go public a little over a week before bankers and industry watchers expect a slight post …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Radiopharmaceuticals startup RayzeBio submits IPO pitch, foreshadowing expected post-Labor Day bump in biotech listings

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

European drug regulator reverses opinion on Eisai and Biogen's Alzheimer's drug

Novo Nordisk to phase out its production of human insulin pens globally

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Ra­dio­phar­ma­ceu­ti­cals start­up Rayze­Bio sub­mits IPO pitch, fore­shad­ow­ing ex­pect­ed post-La­bor Day bump in biotech list­ings

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Radiopharmaceuticals startup RayzeBio submits IPO pitch, foreshadowing expected post-Labor Day bump in biotech listings

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

European drug regulator reverses opinion on Eisai and Biogen's Alzheimer's drug

Novo Nordisk to phase out its production of human insulin pens globally

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?